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Abstract
Background: In drug discovery research, cell-based phenotypic screening is an essential method for obtaining
potential drug candidates. Revealing the mechanism of action is a key step on the path to drug discovery. However,
elucidating the target molecules of hit compounds from phenotypic screening campaigns remains a difficult and
troublesome process. Simple and efficient methods for identifying the target molecules are essential.
Results: 2-Amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine (AMBMP) was identified as a
senescence inducer from a phenotypic screening campaign. The compound is widely used as a Wnt agonist, although
its target molecules remain to be clarified. To identify its target proteins, we compared a series of cellular assay results
for the compound with our pathway profiling database. The database comprises the activities of compounds from
simple assays of cellular reporter genes and cellular proliferations. In this database, compounds were classified on the
basis of statistical analysis of their activities, which corresponded to a mechanism of action by the representative
compounds. In addition, the mechanisms of action of the compounds of interest could be predicted using the
database. Based on our database analysis, the compound was anticipated to be a tubulin disruptor, which was
subsequently confirmed by its inhibitory activity of tubulin polymerization.
Conclusion: These results demonstrate that tubulin is identified for the first time as a target molecule of the
Wnt-activating small molecule and that this might have misled the conclusions of some previous studies. Moreover,
the present study also emphasizes that our pathway profiling database is a simple and potent tool for revealing the
mechanisms of action of hit compounds obtained from phenotypic screenings and off targets of chemical probes.
Background
Drug candidate selection through small-molecule screening
is a rational and widespread method in the current drug
discovery cascade. Initially, drug discovery research in-
volved cell-based phenotypic screening as a core approach
to obtaining drug candidates [1]. However, since the com-
pletion of the Human Genome Project in 2003 and the
finding that sequences include numerous potential target
proteins for drug discovery, target-based drug screening
has been pursued actively [2, 3]. In addition, target-based
drug screening procedures were initially accelerated to in-
crease the research and development productivity of drug
discovery in pharmaceutical companies. However, the num-
ber of FDA-approved drugs screened from the target-based
approach was much less than expected because a large
number of drug candidates failed during drug development
owing to safety issues and a lack of efficacy [4]. In contrast,
recent analysis of all first-in-class new molecular entities
showed that phenotypic screening approaches accounted
for 37 % in comparison with 23 % from target-based
approaches [1]. Accordingly, classical cellular phenotypic
screenings, also called phenotypic drug discovery (PDD),
are being reevaluated as complementary and efficient strat-
egies for probing drug candidates.
Chemical probes are powerful tools for target validation
of hit compounds from PDD. However, some well-known
chemical probes have been used incorrectly and have
resulted in misleading biological conclusions [5]. There-
fore, target identification of these compounds is essential
for PDD. To date, target identification methods that use
chemical proteomics or activity-based proteomics have
been developed, and they have uncovered many unique
target proteins associated with bioactive compounds
[6, 7]. Although they are certainly useful methods, they
require mass spectrometry instrumentation and further
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chemical syntheses to add tags to compounds of interest
without deteriorating their activities. To determine the
target molecules of compounds without affinity tags, Pet-
rone et al. developed the chemical biological descriptor
“high-throughput screening finger-print (HTS-FP)” that
employs accumulated HTS data [8]. On the other hand,
Frederick et al. developed a screening platform that con-
sists of a series of reporter gene assays to disclose the
mechanisms of action (MOAs) of compounds and by con-
ducting assays in a quantitative HTS format [9, 10]. To
develop a much simpler target identification approach
with tag-free compounds, we exploited a pathway profil-
ing database using only tens of cellular assays representing
cellular signaling cascades through evaluation of com-
pounds at a single concentration.
Oncology has become one of the largest therapeutic areas
in the pharmaceutical industry. Various kinds of molecular
targets and cellular signals have been reported to inhibit
cancer growth. Among them, cellular senescence is consid-
ered to be the most important cellular phenotype for per-
manently arresting the cell cycle [11]. To date, reports have
shown that genetic mutations and cellular stressors such as
oxidative stress enhance cellular senescence and that some
small molecules induce cellular senescence [12, 13]. In
particular, compounds that induce cellular senescence are
expected to be potent drugs for suppressing cancer growth
[14]. Here we conducted a phenotypic screening campaign
based on high-content cellular imaging to probe small mol-
ecules that induce cellular senescence.
Results
Pathway profiling database classifies compounds
according to their MOA
The pathway profiling database mainly comprises reporter
gene assays using firefly luciferase that cover 13 different
signaling pathways and cellular proliferation assays with 7
commercially available cell lines (Table 1). These types of
cellular assays are widely used in cell biology research and
are highly accessible because of their simple procedures
and low cost. In addition, these assays are very robust and
demonstrate high throughput, which enabled us to de-
tect subtle signal changes in an HTS-compatible for-
mat. The assays were functionally validated using the
dose-dependent response of a natural ligand or known
inhibitors/activators.
Through the development of this database, we evaluated
1910 compounds from 3 commercial compound libraries
that contained compounds with well-characterized MOAs
and common experimentally used reference compounds.
We evaluated these libraries at a single concentration of
3 μg/mL for the Natural Product Library and at 3 μM for
the other libraries. After obtaining all data, the database
was analyzed using hierarchical clustering of the activities
using Ward’s method in TIBCO Spotfire software (Fig. 1a).
As a result of the hierarchical clustering analysis, com-
pounds that had similar activities in most assays were
classified into the same cluster, enabling us to visually
determine that they have similar molecular targets and
signaling pathways.
Forskolin (Fig. 2), an adenylate cyclase activator [15], was
included in each library, and all were grouped into one
cluster (Fig. 1b). In the cluster, N-ethylcarboxamidoade
nosine (NECA) (Fig. 2), an adenosine receptor agonist [16],
was also included. This cluster was shown to gather com-
pounds stimulating cAMP production via adenylate cyclase
activation. This result indicates that the pathway profiling
database classifies compounds according to their MOA.
Similarly, phorbol 12-myristate 13-acetate (PMA) [17] and
its structural analogs phorbol 12,13-dibutyrate [18], 13-O-
acetylphorbol [19], and 12-deoxyphorbol 13-phenylacetate
20-acetate (dPPA) [20] (Fig. 2) were classified into the same
cluster (Fig. 1c). In other words, the structural analogs that
had the same effect on cellular signaling were categorized
into one cluster, as expected.
Following these analyses, we investigated structurally
diverse compounds that affect the same target proteins. We
focused on the phosphodiesterase (PDE) inhibitors [21–24]
(Fig. 2) contained in our database. To quantitatively com-
pare differences in the structures and activities of each
compound in our database, we employed Tanimoto struc-
tural similarity calculated by Daylight’s fingerprints and
Pearson’s correlation coefficients (activity versus activity),
respectively. The Tanimoto similarities ranged from 0.16 to
0.65, strongly indicating the broad structural diversity be-
tween the compounds in our database (Fig. 1d). In contrast,
Table 1 Constituents of the pathway profiling database. The
types of cellular signals for the reporter gene assays and cell
lines of the proliferation assays are shown
Cellular reporter gene assays Cellular proliferation assays
cAMP response element (CRE) signal HEK293T
Nuclear factor of activated T-cells
(NFAT) signal
MRC5 (high density)
Nuclear factor kappa- light-chain-enhancer
of activated B cells (NF-kB) signal
MRC5 (low density)
Serum response element (SRE) signal A549
Serum response factor (SRF) signal PC3
p53 signal LNCaP
E2F signal Jurkat
Activating transcription factor 6 signal MDA-MB-231
Hedgehog signal
Hypoxia-inducible factor 1 (HIF1) signal
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Fig. 1 Analysis of the pathway profiling database. a The heat map was visualized with TIBCO Spotfire software for clustering analysis. This figure
represents the entire heat map of the pathway profiling database. The activities of each assay are displayed as a gradient from minimum activities
(blue) to maximum activities (red). For details of the assay lists, see Table 1. b This cluster contained forskolin derived from each commercial
compound library and NECA, a potent adenosine receptor agonist. c PMA and its structural analogs were grouped in the cluster shown. d The
Tanimoto structural similarities and Pearson’s correlation coefficients (activity versus activity) were calculated for PDE4 inhibitors
Fig. 2 Chemical structures of the compounds discussed in this study
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Pearson’s correlation coefficients (activity versus activity) in
our database ranged from 0.64 to 0.83 (Fig. 1d), showing
their high bioactive similarities, despite their low structural
similarities. These results indicate that our pathway profil-
ing database based on the biological activities of com-
pounds led to classifications corresponding to not only
their structural similarities but also their MOAs.
Wnt-activating small molecule is identified as a cellular
senescence inducer
Triple-negative breast cancer has been a focus among the
various cancer classes because of its lack of response to
hormonal therapies, and new drugs with distinct MOAs
are absolutely required to cure breast cancer patients [25].
Therefore, we employed MDA-MB-231 cells with triple-
negative features to obtain cellular senescence inducers as
anticancer agents [26]. In this strategy, we performed
phenotypic screening on the basis of high-content cellular
imaging, which is a very useful method to analyze altered
cellular morphology. The cellular senescence morphology
was reported to lead to a topologically enlarged appearance
[11]. Sodium butyrate is a well-known senescence inducer
[27], and we confirmed that it provoked the reported senes-
cence phenotype in MDA-MB-231 cells and expanded cell
shapes (Fig. 3a). In our study, this cellular morphology was
defined as an indicator of cellular senescence.
Fig. 3 A cell-based assay for a screening campaign of cellular senescence morphology inducers by fluorescence microscopy. a MDA-MB231 cells were
treated with 1 mM sodium butyrate. Hoechst 33342 was used as a nuclear marker (blue) and CMFDA was used to mark cytosols (green). Scale bar, 10 μm.
b A compound selection scheme for the discovery of senescence inducers. AMBMP was obtained as a hit compound through the screening campaign.
c Hit compound results from the screening campaign. Fold changes in the cellular area at 3 μM concentrations were calculated for the compounds with
a custom-made image analysis algorithm. d Activity of the Wnt reporter gene assay with a potent GSK3β inhibitor, SB216763, and AMBMP is shown. The
results are the mean of 3 replicate experiments (mean ± SD). e MDA-MB231 cells were treated with 3 μM SB216763, 3 μM AMBMP, and 1 mM sodium
butyrate. Hoechst 33342 was used as a nuclear marker (blue) and CMFDA was used to mark cytosols (green). Scale bar, 10 μm
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For high-content screening (HCS) of senescence in-
ducers, we developed a cell-based assay to analyze cellular
phenotypic changes in MDA-MB-231 cells. To determine
the activities of compounds in this HCS, the cellular area,
which plays a key role in the selection of senescence in-
ducers, was calculated using a custom-made image analysis
algorithm. We screened 1408 compounds in Tocriscreen
(TOCRIS Bioscience) and StemSelect Small Molecule
Regulators (Merck Millipore) at concentrations of 3 μM
and obtained 20 compounds that induced a ≥2-fold en-
largement of the cytosolic area (Fig. 3b). Of these 20
compounds identified as senescence inducers (Fig. 3c), mo-
lecular targets of 19 compounds have been clarified in past
studies, but that of 2-amino-4-(3,4-(methylenedioxy)benzy-
lamino)-6-(3-methoxyphenyl)pyrimidine (AMBMP) (Fig. 2)
has not been revealed yet. Thus, we focused on AMBMP to
elucidate its molecular target, which is described further in
this report.
It is generally considered that Wnt signaling pathways
play important roles during embryonic development [28].
AMBMP was first identified as a Wnt signal agonist
through Wnt signal activator screening using a common
reporter gene assay [29]. To date, the first report of
AMBMP has been cited in 68 papers, and the compound
itself and its 10 applications have been patented (SciFin-
der®). However, its binding proteins have not yet been
identified. We initially measured the activity of AMBMP
using a Wnt reporter gene assay, as reported previously by
Liu et al. [29]. Unexpectedly, using the Wnt reporter assay,
we detected a much lower efficacy of AMBMP than that
of a widely known Wnt signal activator glycogen synthase
kinase 3β (GSK3β) inhibitor (SB216763) [30] (Figs. 2 and
3d). In contrast, GSK3β inhibitors were not observed to
induce the senescence morphology (Fig. 3e, Additional file
1: Figure S1). These results strongly suggest that Wnt
signal activation is not directly related to its cellular senes-
cence and that AMBMP has binding proteins responsible
for inducing cellular senescence.
Pathway profiling database identifies tubulin as a target
protein of AMBMP
To identify an AMBMP target molecule, we compared the
cellular assays with our pathway profiling database and
calculated each Pearson’s correlation coefficient (activity
versus activity) between AMBMP and other all compounds
in our database. As a result, 12 compounds demonstrated
values above 0.8, which indicated high similarities (Fig. 4a).
Moreover, 10 of the 12 compounds involved classical tubu-
lin disruptors such as nocodazole (Fig. 2) and were thus
known from previous reports to bind to tubulin [31–
33]. Of these 10 compounds, only 2, KF 38789 and
chromeceptin, had not been reported to induce tubulin
depolymerization. The analyzed data allowed us to pre-
dict that AMBMP would directly interact with tubulin.
To test this hypothesis, we measured the tubulin disrup-
tion activity of AMBMP in a tubulin polymerization assay.
Consequently, tubulin polymerization was detected by
fluorescence enhancement following uptake of a fluores-
cent reporter molecule into the polymerized tubulin dur-
ing polymerization [34].
We observed tubulin polymerization inhibition by
AMBMP and nocodazole with IC50 values of 0.33 μM and
0.34 μM, respectively (Fig. 4b, Additional file 1: Figure
S2A). In this fluorescence-based polymerization assay,
AMBMP was confirmed not to mediate the fluorescence
interference through the observation of its UV–vis and
fluorescence spectrum (Additional file 1: Figure S3). In
addition, intrinsic fluorescence quenching was used to
study the potential interaction between AMBMP and tubu-
lin. The fluorescence intensity of tubulin was decreased
gradually with increasing concentrations of AMBMP, con-
firming its binding to tubulin. (Fig. 4c). To determine the
effects of these 2 compounds on the cellular microtubule
network, we conducted a cell-based assay using cellular
imaging techniques and fluorescent staining of tubulin. In
the confocal image analysis, AMBMP and nocodazole were
observed to clearly disrupt the intracellular microtubule
network compared to control and SB216763-treated cells
(Fig. 5A). Disturbance of the microtubule network by
AMBMP and nocodazole was detected with IC50 values of
0.34 μM and 1.7 μM, respectively (Additional file 1: Figure
S2B). Furthermore, AMBMP as well as nocodazole was
observed to inhibit cell proliferation and induce a cell cycle
arrest in MDA-MB-231 cells (Additional file 1: Figure S4A,
S4B). The effect of AMBMP on mitotic spindles was also
observed with slightly shortening the spindle and astral
microtubule at the low concentration of 30 nM and with
significantly disrupting mitotic spindles at the higher con-
centrations of 0.3 and 3 μM (Fig. 5B), which was consistent
with previous reports showing the effect of microtubule
disruptors on mitotic spindles [35]. These results indicate
that AMBMP had a strong inhibitory effect on tubulin
polymerization, comparable to that of nocodazole. In
addition, we had previously observed in our screening
campaign that common tubulin disruptors induce cellular
senescence (Fig. 3c) [36, 37].
Discussion
In our study, the pathway profiling database based on the
biological activities of compounds was confirmed to lead to
classifications corresponding to both their structural simi-
larities and their MOAs. Through operating the system, we
will both maintain and obtain data at a lower cost and in a
shorter period than the HTS-FP database and BioMAP™
(DiscoveRx), in which primary cells were utilized. However,
our prediction method is limited to the range of target
molecules of the reference compounds; however, to over-
come this limitation, we will add various reference data for
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compounds that affect different types of target proteins
other than those of the current compounds. In general, the
accuracy of clustering analysis increases with a larger col-
lection of datasets. Therefore, we will expand the cellular
assays in the pathway profiling database to improve the
accuracies of predicting both target molecules and cellular
signaling properties. With these improvements in our sys-
tem, we are attempting to perform target identification of
other compounds, including our in-house compounds, with
unknown targets.
In addition, we estimated the extent of cellular signaling
pathways covered by our database through a computa-
tional approach. With Reactome Pathway Database [38],
our pathway profiling database has the potential to de-
tect cellular events involved in more than 200 canonical
biological pathways. Moreover, 70 % of the tested com-
pounds with well-characterized MOAs had detectable ac-
tivity in at least one assay in our database. Consequently,
our simple system is a promising and cost-effective tool for
profiling phenotypes and for predicting molecular targets of
hit compounds from PDD.
By applying our profiling system for target identification
of AMBMP, we have revealed that AMBMP is a tubulin
disrupting molecule for the first time since the compound
was reported as a Wnt agonist. The Tanimoto similarities
between AMBMP and tubulin disruptors ranged from
0.12 to 0.26 (Fig. 4a), which means that these compounds
are apparently not structural analogs of AMBMP. Because
of their low scores, the structural similarities did not lead
us to hypothesize whether AMBMP could inhibit tubulin
Fig. 4 Target identification of AMBMP and its binding activity to tubulin. a The Tanimoto structural similarities and Pearson’s correlation coefficients
(activity versus activity) were calculated against AMBMP. b SB216763, AMBMP, and nocodazole were evaluated in a tubulin polymerization assay. The
results are the mean of 3 replicate experiments (with SD not shown for graphical simplicity). c AMBMP induced intrinsic tryptophan fluorescence
spectra changes of tubulin. The results are the mean of 3 replicate experiments (with SD not shown for graphical simplicity)
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polymerization. The achievement of AMBMP target
identification supports the result that our pathway profil-
ing database was extremely useful for predicting various
pharmacological targets of compounds with unknown
mechanisms. On the other hand, we consider that it is
important to reveal the molecular mechanisms inhibiting
tubulin polymerization by AMBMP. To address the issue,
in future study, we will clarify its binding site on tubulin
through a cocrystal structural analysis for AMBMP and
tubulin complex.
Chemical probes are widely used to demonstrate target
molecule proof-of-concept in drug discovery [39]. To this
end, the selectivity of chemical probes against the intended
targets is a key factor. If these chemical probes interact with
unintentional molecules and induce cellular phenotypes
through their off-target effects, then both time and money
might be lost in the process of drug discovery research.
Some past research that used AMBMP as a chemical probe
for Wnt signal activation might have incorrectly generated
misleading results due to inhibition of tubulin activity.
Recently, the met proto-oncogene (c-MET) inhibitor tivan-
tinib was confirmed to inhibit tubulin polymerization as
well as AMBMP [40]. Through our study, KF 38789 and
chromeceptin were also shown to have similar bioactive
profiles to tubulin disruptors (Fig. 4b), generating the possi-
bility that both compounds interact with tubulin. These
compounds will be the subject of a future publication. In
addition, a previous report revealed that the structural
similarities of compounds do not provide sufficient infor-
mation to speculate on their biological activities [41]. For
an efficient drug discovery process, it is important to
evaluate and profile chemical probes using various types of
cellular assays, such as our pathway profiling database.
Conclusion
Our pathway profiling database determined tubulin to be a
target of AMBMP, which was unknown since the discovery
of AMBMP, and our simple and efficient system proved to
be a powerful method for predicting compound MOAs.
AMBMP has been widely used as a chemical probe for
Wnt signal activation, but the results for studies that used
the compound might have been influenced by its modula-
tion of tubulin activity and not Wnt signal activity. For
proper utilization of chemical probes, it is potentially
valuable to investigate their cellular profiles using multiple
cellular assays, such our pathway profiling database, which
provides beneficial information about representative cellu-
lar signaling processes. Moreover, in drug discovery, off-
target interactions are strongly thought to lead to low
efficacy and significant side effects in clinical trials; there-
fore, the development of target identification and prediction
methods is now definitively required to determine not only
on-target molecules but also off-target molecules. The sys-
tem will certainly keep providing us with useful information
Fig. 5 Effect of AMBMP on the cellular tubulin network and mitotic spindles. (A) The cellular tubulin network (green) was observed by fluorescence
microscopy. Hoechst 33342 was used as a nuclear marker (blue). (a) control. (b) 3 μM SB216763. (c) 3 μM AMBMP. (d) 3 μM Nocodazole. Scale bar, 10 μm.
(B) Control and compounds-treated MDA-MB-231 cells were stained with α-tubulin (green), phospho-histone H3 (red), and nuclei (blue). Phosphorylation
at a highly conserved serine residue (Ser10) in the histone H3 is a key marker during the mitotic phase of the cell cycle. (a) control. (b) 30 nM nocodazole.
(c) 0.3 μM nocodazole. (d) 3 μM nocodazole. (e) 30 nM AMBMP. (f) 0.3 μM AMBMP. (g) 3 μM AMBMP. Scale bar, 10 μm
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for various stages of the drug discovery process through
target prediction and drug safety research.
Methods
Chemical compounds
Tocriscreen (TOCRIS Bioscience), Natural Product Library
(ENZO Life Sciences), and StemSelect Small Molecule
Regulators (Merck Millipore) were all dissolved in DMSO
(10 mM for Tocriscreen and StemSelect and 10 mg/mL for
the Natural Product Library). AMBMP was obtained
from Merck Millipore. Sodium butyrate, nocodazole,
and SB216763 were sourced from Wako.
Cell cultures
HEK293T, MRC5, A549, PC3, LNCaP, Jurkat, MDA-
MB231, NIH-3 T3, and SW480 cells were purchased from
ATCC. HEK293T, A549, MRC5, and MDA-MB-231 cells
were cultured in DMEM containing 4.5 g/L glucose, 10 %
fetal bovine serum (FBS), and penicillin/streptomycin.
Jurkat, LNCaP, SW480, and PC3 cells were cultured in
RPMI 1640 media containing 10 % FBS and penicillin/
streptomycin. NIIH-3 T3 cells were cultured in DMEM
containing 1.5 g/L glucose, 10 % FBS, and penicillin/
streptomycin. All cell culture reagents were purchased from
Wako.
Reporter gene assays in pathway profiling
We developed reporter gene assays using a firefly luciferase
system purchased from Promega. Detailed assay conditions
such as cell lines, cell densities, corresponding ligands, in-
cubation time with compounds, and materials are shown
(Table 2). All assays were performed in a 384-well plate
format. Plasmids were constructed by inserting each re-
sponse element sequence at a multi-cloning site upstream
from firefly luciferase. Transient transfections of all plas-
mids were performed in corresponding cell lines with
Fugene HD (Promega) according to the manufacturer’s in-
structions. In each assay, we validated the assay condition
with its ligand to perform a stable screening campaign (data
not shown). In all assays, all compounds were diluted in
complete media at a concentration of 3 μg/mL (Natural
Product Library) and 3 μM (other libraries) and treated for
the appropriate durations. After the addition of Steady-Glo
(Promega) according to the manufacturer’s instructions,
luminescence signals were measured using a luminescence
plate reader (EnVision; PerkinElmer). We typically ob-
tained 2 parameters calculated from each assay: one was
Table 2 Assay conditions such as cell lines, cell densities, corresponding ligands, incubation time with compounds, and materials for









cAMP response element (CRE) signal HEK293T 5,000 Forskolin (1 μM) 5 h pGL4.29
(Promega)




Nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-kB) signal
HEK293T 10,000 TNFα (3 ng/mL) 20 h pGL4.32
(Promega)




Serum response factor (SRF) signal HEK293T 20,000 FBS (15 %) 5 h pGL4.34
(Promega)
p53 signal HEK293T 10,000 Doxorubicin (1 μM) 20 h [43]
E2F signal HEK293T 20,000 FBS (15 %) 20 h [44]
Activating transcription factor 6 signal HEK293T 5,000 Thapsigargin (30 nM) 5 h [45]
Hedgehog signal NIH3T3 7,500 mouse sonic hedgehog 20 h [46]
Hypoxia-inducible factor 1 (HIF1) signal HEK293T 10,000 hypoxia 20 h [47]




SMAD signal HEK293T 10,000 TGFβ (0.2 ng/mL) 20 h [48]
Wnt signal HEK293T 10,000 Wnt3a 20 h [49]
Wnt signal SW480 10,000 no ligand (constitutive
active)
20 h [49]
IL17 signal Jurkat 5,000 Ionomycin (400 nM) PMA
(4 ng/mL)
5 h [50]
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the compound’s inhibitory activity with ligand activation
and the other was its agonistic activity without ligand
activation.
Cellular proliferation assays used in pathway profiling
Cell lines, cell densities, and incubation times with com-
pounds are shown (Table 3). Cellular proliferation was
detected with CellTiter-Glo (Promega). All assays were
performed in a 384-well plate format. Luminescence signals
were readout using a luminescence plate reader (EnVision;
PerkinElmer). The proliferation assays with HEK293T cells
and Jurkat cells were used as the counter-screen against
reporter gene assays.
Cell-based phenotypic assays for cellular senescence
inducers
MDA-MB231 cells were seeded in a 384-well plate (3000
cells/well) for 20 h before the treatment of compounds.
After seeding, the tested compounds were diluted in
complete media and incubated with cells for 24 h, followed
by cytosol and nuclear staining for 1 h with CellTracker
Green CMFDA and Hoechst 33342 (Invitrogen), respect-
ively. For cellular tubulin staining, tubulin tracker green
was used according to the manufacturer’s instructions
(Invitrogen). Cellular images were recorded with an IN Cell
Analyzer 6000 (GE Healthcare). After obtaining the images,
the nuclear locations and cellular areas were stained with
Hoechst 33342 and CMFDA, respectively, and quantitative
signals from the images were calculated using a custom-
made image analysis algorithm with IN Cell Developer
Toolbox (GE Healthcare).
Cluster analysis in the pathway profiling system
All compounds were utilized at a concentration of 3 μg/
mL (Natural Product Library) or 3 μM (other libraries) in
the pathway profiling assays. All calculated data, including
percent inhibition and percent activation number, were
first normalized in each assay using the Z-scoring method
and then analyzed by hierarchical clustering analysis
(Ward’s method) with TIBCO Spotfire software (TIBCO).
Calculating Pearson’s correlation coefficients











where N equals 39 assay results and xi and yi are the activ-
ity values of each assay in our pathway profiling database
for compounds A and B, respectively.
Tubulin polymerization assay
Tubulin polymerization was performed using a tubulin
polymerization assay kit (BK011P, Cytoskeleton). Com-
pounds were evaluated according to the manufacturer’s
instructions.
Tubulin binding assay with its intrinsic tryptophan
fluorescence
4 μM of purified tubulin (Cytoskeleton) dissolved in gen-
eral tubulin buffer (80 mM PIPES, pH 6.9, 2 mM MgCl2,
0.5 mM EGTA) was pretreated with certain concentrations
of compounds for 30 min. The intrinsic fluorescence spec-
tra (320–400 nm) was measured with a fluorescence plate
reader (EnVision; PerkinElmer) with the excitation wave-
length 295 nm.
Immunofluorescence microscopy
MDA-MB231 cells were incubated with compounds for
6 h and 24 h to observe the cellular microtubule net-
work and the mitotic spindles respectively. Thereafter,
the cells were fixed and permeabilized as described in
the past report [42]. After blocking nonspecific binding
with 1 % donkey serum/PBS, the cells were incubated
with the mouse monoclonal anti-α-tubulin antibody
(Cell Signaling Technology) (1:1000 dilution) followed
by the Alexa-488 conjugated anti-mouse IgG antibody
(Invitrogen) (1:500 dilution). To visualized nuclei, the
cells were incubated with Hoechst33342. For staining
phospho-Histone H3, the fixed cells were treated with
the rabbit monoclonal anti-phospho-Histone H3 (Ser10)
antibody (Cell Signaling Technology) (1:1000 dilution)
followed by the Alexa-594 conjugated anti rabbit IgG
antibody (Invitrogen) (1:500 dilution). Cellular images
were obtained with SP8 confocal microscopy (Leica).
Flow cytometric analysis
MDA-MB-231 cells were treated with compounds for
24 h, and fixed with ethanol. After fixation, cells were
washed with PBS containing 2 % FCS, and, subsequently,
treated with Guava Cell Cycle reagent (Merck Millipore)
according to the manufacturer's instructions. The DNA
Table 3 Assay conditions such as cell lines, cell densities, and
incubation times for cellular proliferation assays in pathway profiling




HEK293T 5,000 20 h
Jurkat 5,000 20 h
MRC5 1,000 72 h
MRC5 3,500 72 h
A549 1,000 72 h
PC3 1,000 72 h
LNCaP 600 72 h
MDA-MB-231 500 72 h
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contents were determined using a Guava easyCyte HT
software (Merck Millipore).
Additional file
Additional file 1: Supplemental results of cell-based assays and tubulin
polymerization assay. Figure S1. Measurements of fold changes in the
cellular area. Figure S2. Inhibitory activity on the tubulin polymerization and
the cellular microtubule network. Figure S3. The absorbance and fluorescence
profiles of AMBMP. Figure S4. Measurements of growth inhibitory activity, cell
cycle distribution, and mitotic spindle of MDA-MB231 cells treated with
AMBMP. (DOCX 6384 kb)
Abbreviations
FDA: The Food and Drug Administration; HTS: high-throughput screening.
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